Eterna

Media Coverage

Any Year

October 24, 2023

Episode 24 – Genetic engineering for allogeneic immunotherapy

Drug Target Review

October 13, 2023

The impact of cell therapies on cancer treatments

PMLiVE

September 6, 2023

Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies

Exec Edge

August 14, 2023

mRNA-engineered iPSC-derived Cell Therapies Hold Potential for Tackling Solid Tumors

CGTLive

The promise of iPSC-based multi-cell therapeutics

Drug Target Review

Tapping the Potential of mRNA in Cellular Reprogramming and Beyond

Longevity Technology

Eterna Therapeutics Appoints Megan Yung as CSO, General Counsel

Exec Edge

Kyle Garland, PhD on the Potential of mRNA-engineered iPSC-derived Cell Therapies for Solid Tumors

CGTLive

Eterna Acquires Allogeneic Immuno-Oncology Platform from Exacis

Labiotech

Exclusive: RNA Firm Eterna Therapeutics Buys Neighboring Startup for $50M

Boston Business Journal

1 of 2